Kimia Biosciences closes trading window from October 1 ahead of Q2FY27 results
- Trading window closes from October 1, 2026, until 48 hours after Q2FY27 results are declared
- Restriction applies to promoters, directors, designated persons, and immediate relatives
- Board meeting date for financial approval will be disclosed separately later
- Compliance follows SEBI (Prohibition of Insider Trading) Regulations, 2015
*this image is generated using AI for illustrative purposes only.
Kimia Biosciences Limited has announced the closure of its trading window effective October 1, 2026. The restriction will remain in place until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026.
Regulatory compliance and scope
The decision is taken pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. It aligns with the company's internal Code of Conduct for regulating, monitoring, and reporting of trading by designated persons. The closure applies to all promoters, members of the promoter group, directors, designated persons, their immediate relatives, and other individuals covered under the code.
Board meeting schedule
The specific date for the board meeting to consider and approve the financial results has not been finalized. Kimia Biosciences stated that this date will be intimated separately in due course, in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key details of the trading window closure
| Parameter | Detail |
|---|---|
| Effective Date | October 1, 2026 |
| End Date | 48 hours after Q2FY27 results declaration |
| Period Covered | Quarter and half-year ended September 30, 2026 |
| Regulatory Basis | SEBI (PIT) Regulations, 2015 |
| Signatory | Abhishek K. Pandey, Company Secretary & Compliance Officer |
Historical Stock Returns for Kimia Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.13% | +1.31% | +10.71% | +31.63% | -13.89% | -26.89% |
How might the anticipated Q2FY27 financial performance influence Kimia Biosciences' stock volatility once the trading window reopens?
What specific strategic initiatives or pipeline updates are investors expecting to be disclosed alongside the upcoming financial results?
Will the delay in finalizing the board meeting date signal potential complexities in the current quarter's accounting or revenue recognition?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
